Rodeo Therapeutics was founded by Accelerator Life Science Partners based on research collaboration from UT Southwestern and Case Western Reserve University School of Medicine. Rodeo focused on developing small molecule therapies that increase tissue levels of prostaglandin PGE2. The company was acquired by Amgen Inc. in March 2021 for a $55 million upfront payment as well as future contingent milestone payments potentially worth up to an additional $666 million. Amgen, a biotechnology pioneer since 1980, focuses on delivering human therapeutics to meet unmet medical needs.

Founded in 2017, Acquired in 2021